The role of induction therapy for resectable non-small cell lung cancer

Drugs

Volumn 67, Issue 3, 2007, Pages 321-332

  Stinchcombe, Thomas E ^a,b   Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Multidisciplinary Thoracic Oncology Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LOMUSTINE; MITOMYCIN; PACLITAXEL; VINBLASTINE; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; MEDIASTINUM LYMPH NODE; META ANALYSIS; PATIENT SELECTION; PREVALENCE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOADJUVANT THERAPY; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION;

EID: 33947197293     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767030-00001     Document Type: Review

References (50)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30
2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24 (28): 4539-44
3. Bulzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102-10
4. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005; 128: 452-62
5. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Thorac Cardiovasc Surg 2001; 121: 472-83
6. Rendina EA, Venuta F, De Giacomo T, et al. Induction chemotherapy for T4 centrally located non-small cell lung cancer. J Thorac Cardiovasc Surg 1999; 117: 225-33
7. Albain KS, Rusch K, Crowley J, et al. Long term survival after concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery in bulky, stages IIIA (N2) and IIIB non-small cell lung cancer: 6-year outcomes from Southwest Oncology Group Study 8805 [abstract no. 1801]. 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta (GA). Pro Am Soc Clin Oncol 1999; 19: 467a
8. Pisters KM, Le Chevalier T. Adjuvant chemotherapy in completely resected non-small-cell lung cancer. J Clin Oncol 2005; 23: 3270-8
9. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111 (6): 1710-7
10. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-909
11. Douillard JY, Rosell R, Delena M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small cell lung cancer (NSCLC) patients: final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association [abstract no. 7013]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23: 624s
12. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-97
13. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-60
14. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer: report of cancer and leukemia Group B Protocol 9633 [abstract no. LBA7019]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA). J Clin Oncol 2004; 22: 621s
15. Strauss GM, Herndon II JE, Maddaus MA, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633 [abstract no. 7007]. 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA). J Clin Oncol 2006; 24: 365s
16. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-8
17. Slebos RJ, Hruban RH, Dalesio O, et al. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst 1991; 83: 1024-7
18. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999; 17: 668-75
19. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990; 323 (9): 561-5
20. Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol 2006; 19: 448-57
21. Camps C, Sirera R, Bremnes R, et al. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer 2005; 50: 339-46
22. Aviel-Ronen S, Blackhall FH, Shepherd FA, et al. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer 2006; 8: 30-8
23. Pass H, Pogrebniak H, Steinberg S. Randomized trial of neoadjuvant therapy for lung cancer interim analysis. Ann Thorac Surg 1992; 53: 992-8
24. Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21: 1-6
25. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-80
26. DePierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with surgery in resectable stage I (except TINO), II, and IIIA non-small cell lung cancer. J Clin Oncol 2002; 20: 247-53
27. Nagai K, Tsuchiya R, Mori T, et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 2003; 125: 254-60
28. Pisters K, Vallieres E, Bunn PA, et al. S9900: a phase III trial of surgery alone or preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results [abstract no. 7012]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005: 23: 624s
29. Mattson KV, Abratt RP, ten Velde G, et al. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study. Ann Oncol 2003; 14 (1): 116-22
30. Pisters K, Ginsberg R, Giroux DJ, et al. Bimodality Lung Oncology Team (BLOT) trial of induction paclitaxel/carboplatin in early stage non-small cell lung cancer (NSCLC): long term follow-up of a phase II trial [abstract 2544]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL). Proc Am Soc Clin Oncol 2003; 22: 633
31. Scagliotti G. Preliminary results of the CHEST: a phase III study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in clinical early stages non-small cell lung cancer (NSCLC) [abstract no. LBA7023]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23: 626s
32. van Meerbeeck JP, Kramer G, van Schil PE, et al. A randomized trial of radical surgery (S) versus thoracic radiotherapy (TRT) in patients (pts) with stage IIIA-N2 non-small cell lung cancer (NSCLC) after response to induction chemotherapy (ICT) (EORTC 08941) [abstract no. LBA7015]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23: 624s
33. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309) [abstract no. 7014]. 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 13-17; Orlando (FL). J Clin Oncol 2005; 23: 624s
34. Johnstone DW, Byhardt RW, Ettinger D, et al. Phase III study comparing chemotherapy and radiotherapy with preoperative chemotherapy and surgical resection in patients with non-small-cell lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54: 365-9
35. Shepherd FA, Johnston MR, Payne D, et al. Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group Study. Br J Cancer 1998; 78: 683-5
36. Andre F, Grunenwald D, Pignon JP, et al. Survival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implications. J Clin Oncol 2000; 18: 2981-9
37. Albain K, Rusch V, Crowley J, et al. Long-term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stage IIIA (N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group Study 8805 [abstract no. 1801]. 35th Annual Meeting of the American Society of Clinical Oncology; 1999 May 15-18; Atlanta (GA). Proc Am Soc Clin Oncol 1999; 18: 467a
38. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21: 1752-9
39. Albain K, Scott C, Rusch V, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from Intergroup trial 0139 (RTOG 93-09) [abstract no. 2497]. 39th Annual Meeting of the American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL). Proc Am Soc Clin Oncol 2003; 22: 621
40. Bueno R, Richards WG, Swanson SJ, et al. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000; 70: 1826-31
41. Voltolini L, Luzzi L, Ghiribelli C, et al. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy. Eur J Cardiothorac Surg 2001; 20: 1106-12
42. Detterbeck F, Ma S. Induction therapy and surgery for stage I-IIIA,B non-small lung cancer. In: Detterbeck F, Socinski M, Rivera M, et al., editors. Diagnosis and treatment of lung cancer. Philadelphia (PA): W.B. Saunders 2001: 267-82
43. Detterbeck FC, Socinski MA. Induction therapy and surgery for I-IIIA,B non-small cell lung cancer. In: Detterbeck FC, Socinski MA, Rivera MC, et al., editors. Diagnosis and treatment of lung cancer: an evidence-based guide for the practising clinician. Philadelphia (PA): W.B. Saunders Company, 2001: 267-82
44. Van Schil P, van der Schoot J, Poniewierski J, et al. Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. Lung Cancer 2002; 37: 281-5
45. Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, et al. Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2000; 70: 391-5
46. De Leyn P, Stroobants S, De Wever W, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006; 24: 3333-9
47. Solomon B, Mitchell JD, Bunn PA. Adjuvant chemotherapy for resected non-small cell lung cancer. Oncology 2005; 19: 1685-97
48. Fleck CJ, Camargo K, Godoy D, et al. Chemoradiation therapy (CRT) versus chemotherapy (CT) alone as neo-adjuvant treatment for stage III non-small cell lung cancer (NSCLC): preliminary report of a phase III prospective randomized trial [abstract 1108]. Proc Am Soc Clin Oncol 1993; 12: 333
49. Sauvaget RJ-L, Rebischung J, Vannetzel J-M, et al. Phase III study of neo-adjuvant MVP versus MVP plus chemoradiotherapy in stage III disease [abstract]. Proc Am Soc Clin Oncol 2000; 19: a1935
50. Ruebe C, Riesenbeck D, Semik M, et al. Neoadjuvant chemotherapy followed by preoperative radiochemotherapy plus surgery or surgery plus post-operative radiotherapy in stage III non-small cell lung cancer: results of a randomized phase III trial of the German Lung Cancer Cooperative Group [abstract]. Int J Radiat Oncol Biol Phys 2004; 60: S130